ClinicalTrials.gg
CompletedNCT04248829Updated Jun 29, 2026Results posted

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

A Phase 3 interventional study of Lazertinib 240 mg/160 mg and Gefitinib 250 mg in Non-Small Cell Lung Cancer, sponsored by Yuhan Corporation. Completed at 80 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Yuhan Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 20
393 · median 67
Started
2020
with 1 other
Phase 3
3 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
4 of 20
Yuhan Corporation

Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lazertinib

lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations

Read the detailed description

YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) that targets both the T790M mutation and activating EGFR mutations while sparing wild type EGFR.

This is a Phase III, Randomized, Double-blind study evaluating the efficacy and safety of YH25448 (240 mg orally, once daily) versus Gefitinib (250 mg orally, once daily) in patients with locally advanced or metastatic NSCLC that is known to be EGFR sensitizing mutation (EGFRm) positive, treatment-naïve and eligible for first-line treatment with an EGFR-TKI.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Locally Advanced EGFR Sensitizing Mutation
  • Metastatic EGFR Sensitizing Mutation
  • EGFR TKI
  • Ex19del
  • L858R
  • First-line
  • YH25448
  • Advanced Non-Small Cell Lung Cancer
  • Adenocarcinoma of lung
  • Non-squamous carcinoma of lung
  • Phase III
  • Lazertinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the lung
  • Locally advanced or NSCLC, not amenable to curative surgery or radiotherapy
  • At least 1 of the 2 common EGFR mutations known to be associated with EGFR TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations
  • Treatment-naïve for locally advanced or metastatic NSCLC
  • score of 0 to 1 with no deterioration over the previous 2 weeks before randomization
  • At least 1 , not previously irradiated and not chosen for during the study Screening period

Exclusion criteria

Exclusion Criteria:

  • Symptomatic and unstable
  • Symptomatic spinal cord compression
  • History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active ILD
  • Any medical conditions requiring chronic continuous oxygen therapy
  • History of any other than the disease under study within 3 years before randomization
  • Any cardiovascular disease as follows:

    • History of symptomatic chronic heart failure or serious cardiac arrhythmia requiring active treatment
    • History of myocardial infarction or unstable angina within 24 weeks of randomization
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    Lazertinib + Gefitinib-matching placebo

    Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule

    Drug: Lazertinib 240 mg/160 mg · Drug: Gefitinib-matching placebo 250 mg

  • Active comparator
    Gefitinib + Lazertinib-matching placebo

    Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule

    Drug: Gefitinib 250 mg · Drug: Lazertinib-matching placebo 240 mg/160 mg

Interventions

  • DrugLazertinib 240 mg/160 mg

    Drug page: Lazertinib

    The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances

    Also known as: YH25448 240 mg/160 mg

  • The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose

    Also known as: Iressa 250 mg

  • DrugLazertinib-matching placebo 240 mg/160 mg

    The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances

    Also known as: YH25448-matching placebo 240 mg/160 mg

  • DrugGefitinib-matching placebo 250 mg

    The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose

    Also known as: Iressa-matching placebo 250 mg

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment

    PFS was defined as the time from randomization until the date of objective progression or death(by any cause whichever comes first based on investigator assessment using RECIST v1.1 and was used to assess the efficacy of lazertinib compared to the gefitinib).

    Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.

Secondary outcomes

  1. Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments

    ORR was defined as the percentage of participants with measurable disease with at least on visit response of complete response(CR) or Partial response(PR) and it was used to further assess the efficacy of lazertinib compared with gefitinib.

    Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.

  2. Duration of Response (DoR) According to RECIST v1.1 by Investigator Assessments

    DoR was defined as the time from the date of first documented response(CR or PR) until the date of documented progression or death, whichever comes first and was used to further assess the efficacy of lazertinib compared with gefitinib.

    Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.

  3. Disease Control Rate (DCR) According to RECIST v1.1 by Investigator Assessments

    DCR was defined as the percentage of participants who have a best overall response of CR or PR or SD(SD at \>= 6weeks prior to any PD event) and was used to further assess the efficacy of lazertinib compared with gefitinib.

    Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.

  4. Depth of Response According to RECIST v1.1 by Investigator Assessments

    The depth of response was defined as the best percent change in the sum of diameters of target lesions in the absense of new lesions or progression of non-target lesions compared to the baseline and was used to further assess the efficacy of lazertinib compared with gefitinib.

    Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression.

  5. Time to Response According to RECIST v1.1 by Investigator Assessments

    Time to Response was defined as the time from the date of randomization until the date of first documented response and was used to further assess the efficacy of lazertinib compared with gefitinib.

    Time frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression.

  6. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death due to any cause and was used to further assess the efficacy of lazertinib compared with gefitinib.

    Time frame: From the randomization to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks. (Up to 29 months per participant.)

  7. Plasma Concentrations of Lazertinib

    To characterize the pharmacokinetics (PK) of lazertinib.

    Time frame: Blood samples collected from each participant at pre-dose, 1 to 3 hours, and 4 to 6 hours post-dose on Day 1 Cycle 1, Day 1 Cycle 2, Day 1 Cycle 5, Day 1 Cycle 9, and Day 1 Cycle 13.

  8. Cerebrospinal Fluid (CSF) Concentrations of Lazertinib

    To characterize the pharmacokinetics (PK) of lazertinib.

    Time frame: A cerebrospinal fluid (CSF) sample once collected from participants with brain metastases, at Cycle 5 Day 1 or afterward.

  9. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Items (QLQ-C30)

    The EORTC QLQ-C30 consists of 30 items and measures cancer participants' functioning (health related quality of life (HRQoL)) and symptoms for all cancer types. Questions can be grouped into 5 multi item functional scales (physical, role, emotional, cognitive, and social); 3 multi item symptom scales (fatigue, pain, nausea/vomiting); a 2 item global HRQoL scale; 5 single items assessing additional symptoms commonly reported by cancer participants (dyspnea, loss of appetite, insomnia, constipation, diarrhea) and 1 item on the financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. * a high score for a functional scale represents a high / healthy level of functioning * a high score for the global health status / QoL represents a high QoL * but a high score for a symptom scale / item represents a high level of symptomatology / problems

    Time frame: Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).

  10. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Lung Cancer 13 Items (EORTC QLQ-LC13)

    The EORTC QLQ-LC13 includes questions assessing cough, hemoptysis, dyspnea, site specific pain (symptoms), sore mouth, dysphagia, peripheral neuropathy, and alopecia (treatment related side effects), and pain medication. The items on both measures were scaled and scored using the recommended EORTC procedures. Raw scores were transformed to a linear scale ranging from 0 to 100, with a higher score representing a higher level of functioning or higher level of symptoms. Provided at least half of the items in the scale were completed, the scale score was calculated using only those items for which values existed.

    Time frame: Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).

  11. Change From Baseline in Euro-Quality of Life-5 Dimension-5 Level (EQ-5D-5L)

    The EQ-5D comprises the following two questionnaires: * The EQ-5D comprises 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension comprises five levels (no problems, slight problems, moderate problem, severe problem, unable/extreme problems). * The EQ VAS records the participants self-rated health status on a vertical graduated (0-100) visual analogue scale. The patient's self-rated health is assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by the EQ-VAS.

    Time frame: Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).

07

Results

Posted Mar 22, 2024

Participant flow

A total of 393 participants were randomized to treatment at 96 study sites in 13 countries.

Participant flow — Overall Study
MilestoneLazertinib 240 mgGefitnib 250 mg
Started196197
Completed10847
Not completed88150
Withdrew: Disease progression44109
Withdrew: Adverse event1918
Withdrew: Withdrawal by subject112
Withdrew: Lost to follow-up01
Withdrew: Death1214
Withdrew: Physician decision24
Withdrew: Any reason not specifically recorded02

Outcome measures

PrimaryProgression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment

PFS was defined as the time from randomization until the date of objective progression or death(by any cause whichever comes first based on investigator assessment using RECIST v1.1 and was used to assess the efficacy of lazertinib compared to the gefitinib).

Time frame:
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Reported as:
Median · Months
Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment
MonthsLazertinib 240 mgGefitnib 250 mg
Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment20.6 (17.8 to 26.1)9.7 (9.2 to 11.3)
SecondaryObjective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments

ORR was defined as the percentage of participants with measurable disease with at least on visit response of complete response(CR) or Partial response(PR) and it was used to further assess the efficacy of lazertinib compared with gefitinib.

Time frame:
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments
Percentage of participantsLazertinib 240 mgGefitnib 250 mg
Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments76.0 (69.4 to 81.8)76.1 (69.6 to 81.9)
SecondaryDuration of Response (DoR) According to RECIST v1.1 by Investigator Assessments

DoR was defined as the time from the date of first documented response(CR or PR) until the date of documented progression or death, whichever comes first and was used to further assess the efficacy of lazertinib compared with gefitinib.

Time frame:
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Reported as:
Median · Months
Duration of Response (DoR) According to RECIST v1.1 by Investigator Assessments
MonthsLazertinib 240 mgGefitnib 250 mg
Duration of Response (DoR) According to RECIST v1.1 by Investigator Assessments19.4 (16.6 to 24.9)8.3 (6.9 to 10.9)
SecondaryDisease Control Rate (DCR) According to RECIST v1.1 by Investigator Assessments

DCR was defined as the percentage of participants who have a best overall response of CR or PR or SD(SD at \>= 6weeks prior to any PD event) and was used to further assess the efficacy of lazertinib compared with gefitinib.

Time frame:
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression, assessed up to 29 months per participant.
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) According to RECIST v1.1 by Investigator Assessments
Percentage of participantsLazertinib 240 mgGefitnib 250 mg
Disease Control Rate (DCR) According to RECIST v1.1 by Investigator Assessments93.9 (89.5 to 96.8)93.9 (89.6 to 96.8)
SecondaryDepth of Response According to RECIST v1.1 by Investigator Assessments

The depth of response was defined as the best percent change in the sum of diameters of target lesions in the absense of new lesions or progression of non-target lesions compared to the baseline and was used to further assess the efficacy of lazertinib compared with gefitinib.

Time frame:
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression.

Results for this outcome have not been posted.

SecondaryTime to Response According to RECIST v1.1 by Investigator Assessments

Time to Response was defined as the time from the date of randomization until the date of first documented response and was used to further assess the efficacy of lazertinib compared with gefitinib.

Time frame:
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomization until progression.

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death due to any cause and was used to further assess the efficacy of lazertinib compared with gefitinib.

Time frame:
From the randomization to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks. (Up to 29 months per participant.)
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsLazertinib 240 mgGefitnib 250 mg
Death4964
Alive/Censored147133
SecondaryPlasma Concentrations of Lazertinib

To characterize the pharmacokinetics (PK) of lazertinib.

Time frame:
Blood samples collected from each participant at pre-dose, 1 to 3 hours, and 4 to 6 hours post-dose on Day 1 Cycle 1, Day 1 Cycle 2, Day 1 Cycle 5, Day 1 Cycle 9, and Day 1 Cycle 13.

Results for this outcome have not been posted.

SecondaryCerebrospinal Fluid (CSF) Concentrations of Lazertinib

To characterize the pharmacokinetics (PK) of lazertinib.

Time frame:
A cerebrospinal fluid (CSF) sample once collected from participants with brain metastases, at Cycle 5 Day 1 or afterward.

Results for this outcome have not been posted.

SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Items (QLQ-C30)

The EORTC QLQ-C30 consists of 30 items and measures cancer participants' functioning (health related quality of life (HRQoL)) and symptoms for all cancer types. Questions can be grouped into 5 multi item functional scales (physical, role, emotional, cognitive, and social); 3 multi item symptom scales (fatigue, pain, nausea/vomiting); a 2 item global HRQoL scale; 5 single items assessing additional symptoms commonly reported by cancer participants (dyspnea, loss of appetite, insomnia, constipation, diarrhea) and 1 item on the financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. * a high score for a functional scale represents a high / healthy level of functioning * a high score for the global health status / QoL represents a high QoL * but a high score for a symptom scale / item represents a high level of symptomatology / problems

Time frame:
Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).

Results for this outcome have not been posted.

SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Lung Cancer 13 Items (EORTC QLQ-LC13)

The EORTC QLQ-LC13 includes questions assessing cough, hemoptysis, dyspnea, site specific pain (symptoms), sore mouth, dysphagia, peripheral neuropathy, and alopecia (treatment related side effects), and pain medication. The items on both measures were scaled and scored using the recommended EORTC procedures. Raw scores were transformed to a linear scale ranging from 0 to 100, with a higher score representing a higher level of functioning or higher level of symptoms. Provided at least half of the items in the scale were completed, the scale score was calculated using only those items for which values existed.

Time frame:
Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).

Results for this outcome have not been posted.

SecondaryChange From Baseline in Euro-Quality of Life-5 Dimension-5 Level (EQ-5D-5L)

The EQ-5D comprises the following two questionnaires: * The EQ-5D comprises 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension comprises five levels (no problems, slight problems, moderate problem, severe problem, unable/extreme problems). * The EQ VAS records the participants self-rated health status on a vertical graduated (0-100) visual analogue scale. The patient's self-rated health is assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by the EQ-VAS.

Time frame:
Questionnaires completed at Cycle 1 Day1 , Cycle2 Day 1 and then every 6 weeks relative to the randomization date until 28d safety f/u or progression f/u visit(whichever is later).

Results for this outcome have not been posted.

Adverse events

Collected over All adverse events (AEs) were collected from the time of signature of informed consent throughout the Treatment Period and including the safety follow-up period.The safety follow-up period was defined as 28 days after study drug was discontinued. (Up to 29 months per participant.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lazertinib 240 mg49/196 (25%)51/196 (26%)189/196 (96.4%)
Gefitnib 250 mg64/197 (32.5%)51/197 (25.9%)188/197 (95.4%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventLazertinib 240 mgGefitnib 250 mg
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/1962/197
PneumoniaInfections and infestations8/1963/197
Acute kidney injuryRenal and urinary disorders1/1964/197
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders3/1961/197
DiarrhoeaGastrointestinal disorders3/1961/197
DeathGeneral disorders3/1963/197
COVID-19Infections and infestations1/1963/197
Pneumocystis jirovecii pneumoniaInfections and infestations0/1963/197
Pleural effusionRespiratory, thoracic and mediastinal disorders2/1961/197
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1960/197
Most frequent other events
Showing 10 of 41
Most frequent other events
EventLazertinib 240 mgGefitnib 250 mg
ParaesthesiaNervous system disorders77/19613/197
DiarrhoeaGastrointestinal disorders51/19677/197
RashSkin and subcutaneous tissue disorders71/19672/197
Alanine aminotransferase increasedInvestigations30/19659/197
PruritusSkin and subcutaneous tissue disorders52/19636/197
Aspartate aminotransferase increasedInvestigations22/19652/197
AnaemiaBlood and lymphatic system disorders36/19623/197
ParonychiaSkin and subcutaneous tissue disorders35/19634/197
Decreased appetiteMetabolism and nutrition disorders33/19631/197
StomatitisGastrointestinal disorders31/19616/197

Baseline characteristics

The full analysis set (FAS), FAS included all randomized participants.

Age, Customized
Age, Customized(years)Lazertinib 240 mgGefitnib 250 mgTotal
Median67 (31 to 87)64 (25 to 86)65 (25 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)Lazertinib 240 mgGefitnib 250 mgTotal
Female132119251
Male6478142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lazertinib 240 mgGefitnib 250 mgTotal
Race — Asian130130260
Race — Non-Asian6667133
Smoking history
Smoking history(Participants)Lazertinib 240 mgGefitnib 250 mgTotal
Never135149284
Former504292
Current11617
08

Study locations

80 sites
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Eugenideio Therapeutirio - Ongcology Department
    Athens, 11528, Greece
  • Attikon Hospital
    Athens, 12462, Greece
  • Theageneio Anticancer Hospital of Thessaloniki
    Thessaloniki, 54007, Greece
  • Debreceni Egyetem
    Debrecen, H-4012, Hungary
  • Törökbálinti Tüdőgyógyintézet
    Törökbálint, 2045, Hungary
  • Hospital Sultan Ismail
    Johor Bahru, Johor 81100, Malaysia
  • Hospital Raja Perempuan Zainab Ii
    Kota Bharu, Kelantan 15586, Malaysia
  • Hospital Tengku Ampuan Afzan
    Kuantan, Pahang 25100, Malaysia
  • Hospital Pulau Pinang
    George Town, Pulau Pinang 10400, Malaysia
  • Hospital Umum Sarawak
    Kuching, Sarawak 10450, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, Selangor 59100, Malaysia
  • Manila Doctors Hospital - Clinical Trial Office
    Manila, Quezon 1000, Philippines
  • Perpetual Succour Hospital
    Cebu, 6000, Philippines
  • Philippine General Hospital
    Manila, 1000, Philippines
  • Arkhangelsk Regional Clinical Oncological Dispensary
    Arkhangelsk, Arkhangelskaya oblast 163045, Russia
  • GBUZ of Nizhny Novgorod region Clinical diagnostic center
    Nizhny Novgorod, Nizhny Novgorod Oblast 603006, Russia
  • GAUZ Republican clinical oncology dispensary of the Ministry
    Kazan', 420029, Russia
  • Republic Clinical Oncology Despensary
    Kazan', 420029, Russia
  • Medincentre (GLAVUPDK)
    Moscow, 119034, Russia
  • VitaMed LLC
    Moscow, 121309, Russia
  • MBUZ City Clinical Hospital #1
    Novosibirsk, Russia
  • Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary"
    Omsk, 644013, Russia
  • Private medical institution "Euromedservice"
    Pushkin, 196603, Russia
  • First St. Petersburg State Medical University n. a. Pavlov
    Saint Petersburg, 197022, Russia
  • LLC "Eurocityclinic"
    Saint Petersburg, 197022, Russia
  • Limited Liability Company "AV Medical Group" - Oncology
    Saint Petersburg, 197082, Russia
  • Saint-Petersburg City Clinical Oncology Dispensary
    Saint Petersburg, 198255, Russia
  • GBUZ "Regional clinical oncologic dispensary of Volgograd"
    Volgograd, 400138, Russia
  • Yaroslavl regional oncology hospital
    Yaroslavl, 150054, Russia
  • Clinical Hospital Center "Bezanijska Kosa"
    Belgrade, Belgrade 11080, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Kamenitz, Vojvodina 21204, Serbia
  • Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • National University Hospital
    Singapore, 119074, Singapore
  • The Catholic University of Korea, Bucheon St. Mary's Hospital
    Bucheon-si, Gyeonggi-do 14647, South Korea
  • National Cancer Center
    Goyang-si, Gyeonggi-do 10408, South Korea
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Gyeonggi-do 13496, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Gyeonggi-do 16247, South Korea
  • Ajou University Hospital
    Suwon, Gyeonggi-do 16499, South Korea
  • Gyeongsang National University Hospital
    Jinju, Gyeongsangnam-do 52727, South Korea
  • Chungbuk National University Hospital
    Cheongju-si, North Chungcheong 28644, South Korea
  • Inje University Haeundae Paik Hospital
    Busan, 48108, South Korea
  • Yeungnam University Medical Center
    Daegu, 42415, South Korea
  • Keimyung University Dongsan Medical Center
    Daegu, 42601, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Kangbuk Samsung Hospital
    Seoul, 03181, South Korea
  • The Catholic University of Korea, Eunpyeong St.Mary's Hospital
    Seoul, 03312, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
  • SMG-SNU Boramae Medical Center
    Seoul, 07061, South Korea
  • Ulsan University Hospital
    Ulsan, 44033, South Korea
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
  • Siriraj Hospital
    Bangkok, 10700, Thailand
  • Chiang Mai University - Faculty of Medicine
    Chiang Mai, 50200, Thailand
  • Prince of Songkla University
    Hat Yai, 90110, Thailand
  • Srinagarind Hospital, Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Adana Baskent Practice and Research Hospital
    Adana, 1120, Turkey (Türkiye)
  • Cukurova University Medical Faculty
    Adana, 1330, Turkey (Türkiye)
  • Ankara Liv Hospital
    Ankara, 06680, Turkey (Türkiye)
  • Hacettepe University Medical Faculty - Medical Oncology
    Ankara, 6230, Turkey (Türkiye)
  • Trakya University Medical Faculty
    Edirne, 22030, Turkey (Türkiye)
  • Istanbul Medeniyet University Goztepe Training and Research Hospital - Medical Oncology
    Istanbul, 34722, Turkey (Türkiye)
  • Medical Point İzmir Hospital
    Izmir, 35560, Turkey (Türkiye)
  • Kocaeli University Medical Faculty
    Kocaeli, 41380, Turkey (Türkiye)
  • Inonu University Turgut Ozal Medical Center
    Malatya, 44280, Turkey (Türkiye)
  • Komunalne nekomertsiine pidpryiemstvo Kharkivskoi oblasnoi rady "Oblasnyi klinichnyi spetsializovanyi dyspanser radiatsiinoho zakhystu naselennia" - khirurhichne viddilennia
    Kharkiv, Kharkiv Oblast 61166, Ukraine
  • Tsentralna miska klinichna likarnia
    Uzhhorod, Zakarpattia Oblast 88000, Ukraine
  • Oblasne komunalne nekomertsiine pidpryiemstvo "Bukovynskyi klinichnyi onkolohichnyi tsentr", strukturnyi pidrozdil klinichnoi onkolohii, m.Chernivtsi
    Chernivtsi, 58013, Ukraine
  • Komunalne nekomertsiine pidpryiemstvo "Miska klinichna likarnia №4" Dniprvskoi miskoi rady", khimioterapevtychne viddilennia z dennym statsionarom, Derzhavnyi zaklad "Dnipropetrovskyi derzhavnyi medychnyi universitet", kafedra onkolohii i medychnoi radio
    Dnipro, 49102, Ukraine
  • Kyiv City Clinical Oncology Center - Department of Chemotherapy
    Kyiv, 3115, Ukraine
  • Komunalne nekomertsiine pidpryiemstvo Sumskoi oblasnoi rady "Sumskyi klinichnyi onkolohichnyi tsentr", onkotorakalne viddilennia, Sumskyi derzhavnyi universytet, kafedra onkolohii ta radiolohii, m. Sumy
    Sumy, 40022, Ukraine
  • Podilskyi rehionalnyi tsentr onkolohii, viddilennia khimioterapii
    Vinnytsia, 21029, Ukraine
  • Medychnyi tsentr Tovarystva z obmezhenoiu vidpovidalnistiu "Onkolaif"
    Zaporizhzhya, 69059, Ukraine
09

References and documents

Publications

  • Soo RA, Cho BC, Kim JH, Ahn MJ, Lee KH, Zimina A, Orlov S, Bondarenko I, Lee YG, Lim YN, Lee SS, Lee KH, Pang YK, Fong CH, Kang JH, Lim CS, Danchaivijitr P, Kilickap S, Yang JC, Arslan C, Lee H, Park SN, Cicin I. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis. J Thorac Oncol. 2023 Dec;18(12):1756-1766. doi: 10.1016/j.jtho.2023.08.017. Epub 2023 Oct 22. PubMed 37865896 ↗
  • Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. PubMed 37379502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to hmbyun@yuhan.co.kr. Other documents(i.e. a summary of the study results, study protocol, statistical analysis plan) will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed.

Access criteria: Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to hmbyun@yuhan.co.kr.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jul 2022, 29 months.

Results were first posted in Mar 2024, 1 year 7 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 29 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 30, 2020
StartActual
Feb 13, 2020
Primary completionActual
Jul 29, 2022
CompletionActual
Apr 22, 2026
Results first posted
Mar 22, 2024
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04248829
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Jan 30, 2020
Start date
Feb 13, 2020
Primary completion
Jul 29, 2022
Completion
Apr 22, 2026
Results posted
Mar 22, 2024
Last update
Jun 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lazertinib

Start the discussion